Evaluation of the pharmacokinetics and safety of TMC125 [etravirine] administered once and twice-daily and following a 2-week-treatment period with efavirenz in male and female healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2009
At a glance
- Drugs Efavirenz; Etravirine
- Indications HIV infections
- Focus Pharmacokinetics
- 01 Oct 2009 Resutls reported in Journal of Acquired Deficiency Syndromes.
- 06 Jun 2008 Status change
- 04 Oct 2007 New trial record.